Landscapes / Companies

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
Approved in China
Next date
Anlotinib Hydrochloride, Phase 2 trial completes
Drugs
18
in active trials · 26 in all
Trials
32 active
53 since 2021

Drugs18

DrugHow it worksPartnerStageNext dateDetails
Tyrosine kinase inhibitor
Chia Tai Tianqing Pharmaceutical Group
Approved in China Nov 2026soonPhase 2 trial completes
—
Phase 3 Nov 2026soonPhase 2 trial completes
—
Phase 3 Dec 2026Phase 1/2 trial completes
—
Phase 3 Jan 2027Phase 3 trial completes
—
Phase 3 Aug 2027Phase 2 trial completes
—
Phase 3 —
—
Phase 2 Dec 2026Phase 2 trial completes
—
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development
Phase 1/2 Dec 2026Phase 1 trial completes
—
Phase 2 17 Mar 2027Phase 2 trial completes
—
Phase 2 Aug 2027Phase 2 trial completes
—
LaNova Medicines
Phase 1/2 —
—
Chia Tai Tianqing Pharmaceutical Group
Phase 1 Oct 2027Phase 1 trial completes
—
Chia Tai Tianqing Pharmaceutical Group
Phase 1 Dec 2027Phase 1 trial completes
—
Phase 1 —
—
Phase 1 —
TQB2928not checked
—
Chia Tai Tianqing Pharmaceutical Group
Phase 1 —
—
Phase 1 —
—
Phase 1 —

About

No active trial
8 other drugs
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Following is part of Solo: you see every change to Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in